For this single case, the FDA approved the early administration of the oral drug risdiplam, brand name Evrysdi, owned by the ...

While Roche’s oral risdiplam has been tipped by some analysts to be a big contender in the market for spinal muscular atrophy (SMA) treatments, Novartis’ research chief Jay Bradner has a ...

Roche had appealed against a single judge order of March 24 that had refused to stop Natco Pharma from manufacturing a generic version of Risdiplam ...

A rare genetic condition, Spinal Muscular Atrophy (SMA) affects one in 7,000 people in India. It mostly affects children and ...

Patients with Spinal Muscular Atrophy (SMA) are hopeful of getting access to generic versions of Roche’s patented drug ...

The FDA has started a priority review of Roche’s spinal muscular atrophy (SMA) candidate risdiplam, with a decision due by 24 May next year. If approved, risdiplam will be the third drug to be ...

So far, the child's lack of symptoms comes as a successful result of the orally administered drug risdiplam, developed by pharmaceutical company Roche, based in Basel, Switzerland. Risdiplam works ...

This means that the Delhi High Court order effectively permits Natco to manufacture Risdiplam. Noting that SMA is a ...

In a major relief to Indian drugmaker Natco Pharma, the Delhi High Court has rejected an interim injunction plea filed by ...

"Roche has filed an appeal against the Hon. Delhi High Court order and the matter is subjudice in the appeal court," Roche ...

The bench said that public good outweighs the company’s profit as the drug is not available at an affordable price in India.

The Delhi High Court has observed that availability of a drug for treatment of rare diseases at economical and competitive ...